Skip to content

Monopar Therapeutics MNPR Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$3.89M+25.1%-$5.2M-51.3%-$3.44M-40.1%-$2.45M+6.5%-$2.62M+76.0%
$1.69M+53.3%$1.1M+0.4%$1.1M-14.1%$1.28M-5.6%$1.36M+386%
-$287.14K-139%$738.68K-$770.97K-168%
$187.04K+126%-$709.4K-761%$107.24K+26.6%$84.72K-83.1%$502.03K+1,587%
-$3.47M-3.1%-$3.37M-61.2%-$2.09M-94.0%-$1.08M+81.0%-$5.66M-183%
$40.84M-47.8%$78.29M+1,267%$5.73M+372%$1.21M-37.0%$1.93M-86.6%
$35.25M+119%$16.1M+347%$3.6M+50.0%$2.4M+50.0%$1.6M
-$5.58M+91.0%-$62.19M-2,825%-$2.13M-279%$1.19M+464%-$325.83K+97.7%
$0$0$0$0$0-100%
$200.2K-32.8%$298.09K-21.9%$381.56K+18.7%$321.56K+145%$131.13K+95.9%
-$200.2K$0-100%$92.39M+29,260%-$316.85K-174%-$115.68K-100%
-$31.63K-132%$99.5K+26,361%$376+115%-$2.55K-4,624%-$54
-$9.29M$88.18M+42,194%-$209.47K+96.6%-$6.1M-115%
$799.63K$119.51K+5,202%
$187.04K+126%-$709.4K-761%$107.24K+26.6%$84.72K-83.1%$502.03K+1,587%
$0$0$0$0-100%
$40.84M-47.8%$78.29M+1,267%$5.73M+372%$1.21M-37.0%$1.93M-86.6%
$35.25M+119%$16.1M+347%$3.6M+50.0%$2.4M+50.0%$1.6M
-$31.63K-132%$99.5K+26,361%$376+115%-$2.55K-4,624%-$54
-$0$3M+200%
$25-99.5%$5K$0-100%$3.58K+321%$850
$291.73K+77.8%$164.09K$0-100%$117.44K+1,086%$9.9K

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Monopar Therapeutics generate?
Monopar Therapeutics (MNPR) generated -$10.0M in operating cash flow over the trailing twelve months.
Where does Monopar Therapeutics's cash flow data come from?
Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.